Analysts Set Expectations for Cryoport, Inc.’s Q2 2025 Earnings (NASDAQ:CYRX)

Cryoport, Inc. (NASDAQ:CYRX) – Investment analysts at Roth Capital issued their Q2 2025 EPS estimates for Cryoport in a research note issued on Wednesday, May 8th. Roth Capital analyst R. Baldry expects that the company will post earnings of ($0.31) per share for the quarter. The consensus estimate for Cryoport’s current full-year earnings is ($1.42) per share. Roth Capital also issued estimates for Cryoport’s Q3 2025 earnings at ($0.28) EPS, Q4 2025 earnings at ($0.28) EPS and FY2025 earnings at ($1.21) EPS.

A number of other equities research analysts also recently issued reports on the company. Jefferies Financial Group assumed coverage on Cryoport in a research note on Thursday, April 4th. They set a “buy” rating and a $21.00 price target for the company. Needham & Company LLC restated a “buy” rating and set a $18.00 target price on shares of Cryoport in a research report on Wednesday. Stephens reiterated an “equal weight” rating and issued a $17.00 price target on shares of Cryoport in a research report on Wednesday, March 13th. B. Riley cut shares of Cryoport from a “buy” rating to a “neutral” rating and dropped their price target for the stock from $22.00 to $19.00 in a research note on Friday, May 3rd. Finally, UBS Group upped their price objective on Cryoport from $14.50 to $17.00 and gave the stock a “neutral” rating in a research note on Friday, March 15th. Six analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. Based on data from MarketBeat.com, Cryoport has an average rating of “Hold” and a consensus target price of $18.25.

Cryoport Stock Performance

Shares of CYRX opened at $13.46 on Thursday. The firm has a market capitalization of $661.75 million, a P/E ratio of -6.12 and a beta of 1.60. The company has a debt-to-equity ratio of 0.82, a current ratio of 11.73 and a quick ratio of 11.16. Cryoport has a one year low of $9.00 and a one year high of $23.50. The business has a fifty day moving average of $16.78 and a 200 day moving average of $15.19.

Cryoport (NASDAQ:CYRX) last announced its earnings results on Tuesday, May 7th. The company reported ($0.43) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.37) by ($0.06). The company had revenue of $54.59 million for the quarter, compared to analysts’ expectations of $58.78 million. Cryoport had a negative net margin of 42.69% and a negative return on equity of 11.86%. Cryoport’s quarterly revenue was down 13.1% on a year-over-year basis. During the same quarter in the prior year, the firm posted ($0.16) earnings per share.

Insiders Place Their Bets

In other news, CEO Jerrell Shelton sold 2,631 shares of the firm’s stock in a transaction on Monday, March 25th. The shares were sold at an average price of $17.54, for a total transaction of $46,147.74. Following the sale, the chief executive officer now directly owns 692,182 shares in the company, valued at approximately $12,140,872.28. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In related news, CEO Jerrell Shelton sold 2,631 shares of the stock in a transaction dated Monday, March 25th. The stock was sold at an average price of $17.54, for a total transaction of $46,147.74. Following the completion of the sale, the chief executive officer now owns 692,182 shares in the company, valued at $12,140,872.28. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Ramkumar Mandalam sold 3,217 shares of the business’s stock in a transaction that occurred on Friday, March 15th. The stock was sold at an average price of $14.68, for a total value of $47,225.56. Following the completion of the transaction, the director now directly owns 43,187 shares in the company, valued at $633,985.16. The disclosure for this sale can be found here. Insiders sold a total of 73,940 shares of company stock worth $1,147,538 over the last three months. 10.10% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Cryoport

Several institutional investors have recently bought and sold shares of the stock. Conestoga Capital Advisors LLC lifted its stake in Cryoport by 1.0% in the 1st quarter. Conestoga Capital Advisors LLC now owns 71,417 shares of the company’s stock worth $1,264,000 after purchasing an additional 690 shares in the last quarter. Arizona State Retirement System increased its holdings in shares of Cryoport by 5.4% in the fourth quarter. Arizona State Retirement System now owns 13,665 shares of the company’s stock worth $212,000 after purchasing an additional 696 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank lifted its position in shares of Cryoport by 13.9% in the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 11,462 shares of the company’s stock worth $157,000 after buying an additional 1,395 shares in the last quarter. Natixis Investment Managers International boosted its stake in Cryoport by 61.5% during the fourth quarter. Natixis Investment Managers International now owns 4,536 shares of the company’s stock valued at $70,000 after buying an additional 1,727 shares during the last quarter. Finally, Advisors Capital Management LLC boosted its stake in Cryoport by 2.5% during the third quarter. Advisors Capital Management LLC now owns 78,993 shares of the company’s stock valued at $1,083,000 after buying an additional 1,947 shares during the last quarter. 92.90% of the stock is owned by hedge funds and other institutional investors.

Cryoport Company Profile

Cryoport, Inc provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and human reproductive medicine markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoport Express Shippers; Cryoport ELITE -80°C Gene Therapy Shipper; Cryoport ELITE Cryosphere Shipper; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; and Cryoport bioservices, such as controlled temperature storage, fulfilment, kit production, secondary packaging, labelling of therapeutic products, and GMP raw materials storage services.